- About
- Strategic Plan
- Structure
- Governance
- Scientific divisions
- ACRF Cancer Biology and Stem Cells
- ACRF Chemical Biology
- Advanced Technology and Biology
- Bioinformatics
- Blood Cells and Blood Cancer
- Clinical Translation
- Epigenetics and Development
- Immunology
- Infectious Diseases and Immune Defence
- Inflammation
- Personalised Oncology
- Population Health and Immunity
- Structural Biology
- Ubiquitin Signalling
- Laboratory operations
- Funding
- Annual reports
- Human research ethics
- Scientific integrity
- Institute life
- Career opportunities
- Business Development
- Collaborators
- Suppliers
- Publications repository
- Awards
- Discoveries
- Centenary 2015
- History
- Contact us
- Research
- Diseases
- Cancer
- Development and ageing
- Immune health and infection
- Research fields
- Research technologies
- Research centres
- People
- Alistair Brown
- Anne-Laure Puaux
- Assoc Prof Joanna Groom
- Associate Profesor Ian Majewski
- Associate Professor Aaron Jex
- Associate Professor Andrew Webb
- Associate Professor Chris Tonkin
- Associate Professor Diana Hansen
- Associate Professor Edwin Hawkins
- Associate Professor Ethan Goddard-Borger
- Associate Professor Gemma Kelly
- Associate Professor Grant Dewson
- Associate Professor Isabelle Lucet
- Associate Professor James Vince
- Associate Professor Jason Tye-Din
- Associate Professor Jeff Babon
- Associate Professor Joan Heath
- Associate Professor John Wentworth
- Associate Professor Justin Boddey
- Associate Professor Kate Sutherland
- Associate Professor Kelly Rogers
- Associate Professor Marie-Liesse Asselin-Labat
- Associate Professor Melissa Call
- Associate Professor Misty Jenkins
- Associate Professor Nawaf Yassi
- Associate Professor Oliver Sieber
- Associate Professor Rachel Wong
- Associate Professor Rhys Allan
- Associate Professor Rosie Watson
- Associate Professor Ruth Kluck
- Associate Professor Shalin Naik
- Associate Professor Sumitra Ananda
- Associate Professor Tim Thomas
- Associate Professor Tracy Putoczki
- Chela Niall
- Deborah Carr
- Dr Alisa Glukhova
- Dr Anna Coussens
- Dr Ashley Ng
- Dr Belinda Phipson
- Dr Ben Tran
- Dr Bernhard Lechtenberg
- Dr Brad Sleebs
- Dr Drew Berry
- Dr Gwo Yaw Ho
- Dr Hamish King
- Dr Hui-Li Wong
- Dr Jacqui Gulbis
- Dr Jim Whittle
- Dr Lucy Gately
- Dr Margaret Lee
- Dr Mary Ann Anderson
- Dr Maryam Rashidi
- Dr Matthew Call
- Dr Nadia Davidson
- Dr Nadia Kershaw
- Dr Philippe Bouillet
- Dr Rebecca Feltham
- Dr Rory Bowden
- Dr Samir Taoudi
- Dr Sarah Best
- Dr Saskia Freytag
- Dr Shabih Shakeel
- Dr Sheau Wen Lok
- Dr Stephin Vervoort
- Dr Yunshun Chen
- Guillaume Lessene
- Helene Martin
- Joh Kirby
- Kaye Wycherley
- Keely Bumsted O'Brien
- Mr Simon Monard
- Mr Steve Droste
- Ms Carolyn MacDonald
- Professor Alan Cowman
- Professor Andreas Strasser
- Professor Andrew Roberts
- Professor Anne Voss
- Professor Clare Scott
- Professor Daniel Gray
- Professor David Huang
- Professor David Komander
- Professor David Vaux
- Professor Doug Hilton
- Professor Geoff Lindeman
- Professor Gordon Smyth
- Professor Ian Wicks
- Professor Ivo Mueller
- Professor James McCarthy
- Professor James Murphy
- Professor Jane Visvader
- Professor Jeanne Tie
- Professor Jerry Adams
- Professor John Silke
- Professor Ken Shortman
- Professor Leanne Robinson
- Professor Leonard C Harrison
- Professor Lynn Corcoran
- Professor Marnie Blewitt
- Professor Matthew Ritchie
- Professor Melanie Bahlo
- Professor Melissa Davis
- Professor Mike Lawrence
- Professor Nicos Nicola
- Professor Peter Colman
- Professor Peter Czabotar
- Professor Peter Gibbs
- Professor Phil Hodgkin
- Professor Sandra Nicholson
- Professor Sant-Rayn Pasricha
- Professor Seth Masters
- Professor Stephen Nutt
- Professor Suzanne Cory
- Professor Terry Speed
- Professor Tony Papenfuss
- Professor Wai-Hong Tham
- Professor Warren Alexander
- Diseases
- Education
- PhD
- Honours
- Masters
- Clinician-scientist training
- Undergraduate
- Student research projects
- A multi-pronged approach to targeting myeloproliferative neoplasms
- A new paradigm of machine learning-based structural variant detection
- A whole lot of junk or a treasure trove of discovery?
- Advanced imaging interrogation of pathogen induced NETosis
- Analysing the metabolic interactions in brain cancer
- Atopic dermatitis causes and treatments
- Boosting the efficacy of immunotherapy in lung cancer
- Building a cell history recorder using synthetic biology for longitudinal patient monitoring
- Characterisation of malaria parasite proteins exported into infected liver cells
- Deciphering the heterogeneity of the tissue microenvironment by multiplexed 3D imaging
- Defining the mechanisms of thymic involution and regeneration
- Delineating the molecular and cellular origins of liver cancer to identify therapeutic targets
- Developing computational methods for spatial transcriptomics data
- Developing drugs to block malaria transmission
- Developing models for prevention of hereditary ovarian cancer
- Developing statistical frameworks for analysing next generation sequencing data
- Development and mechanism of action of novel antimalarials
- Development of novel RNA sequencing protocols for gene expression analysis
- Discoveries in red blood cell production and function
- Discovering epigenetic silencing mechanisms in female stem cells
- Discovery and targeting of novel regulators of transcription
- Dissecting host cell invasion by the diarrhoeal pathogen Cryptosporidium
- Dissecting mechanisms of cytokine signalling
- Doublecortin-like kinases, drug targets in cancer and neurological disorders
- Epigenetic biomarkers of tuberculosis infection
- Epigenetics – genome wide multiplexed single-cell CUT&Tag assay development
- Exploiting cell death pathways in regulatory T cells for cancer immunotherapy
- Exploiting the cell death pathway to fight Schistosomiasis
- Finding treatments for chromatin disorders of intellectual disability
- Functional epigenomics in human B cells
- How do nutrition interventions and interruption of malaria infection influence development of immunity in sub-Saharan African children?
- Human lung protective immunity to tuberculosis
- Improving therapy in glioblastoma multiforme by activating complimentary programmed cell death pathways
- Innovating novel diagnostic tools for infectious disease control
- Integrative analysis of single cell RNAseq and ATAC-seq data
- Interaction with Toxoplasma parasites and the brain
- Interactions between tumour cells and their microenvironment in non-small cell lung cancer
- Investigation of a novel cell death protein
- Malaria: going bananas for sex
- Mapping spatial variation in gene and transcript expression across tissues
- Mechanisms of Wnt secretion and transport
- Multi-modal computational investigation of single-cell communication in metastatic cancer
- Nanoparticle delivery of antibody mRNA into cells to treat liver diseases
- Naturally acquired immune response to malaria parasites
- Organoid-based discovery of new drug combinations for bowel cancer
- Organoid-based precision medicine approaches for oral cancer
- Removal of tissue contaminations from RNA-seq data
- Reversing antimalarial resistance in human malaria parasites
- Role of glycosylation in malaria parasite infection of liver cells, red blood cells and mosquitoes
- Screening for novel genetic causes of primary immunodeficiency
- Single-cell ATAC CRISPR screening – Illuminate chromatin accessibility changes in genome wide CRISPR screens
- Spatial single-cell CRISPR screening – All in one screen: Where? Who? What?
- Statistical analysis of single-cell multi-omics data
- Structural and functional analysis of epigenetic multi-protein complexes in genome regulation
- Structural basing for Wnt acylation
- Structure, dynamics and impact of extra-chromosomal DNA in cancer
- Targeted deletion of disease-causing T cells
- Targeting cell death pathways in tissue Tregs to treat inflammatory diseases
- The cellular and molecular calculation of life and death in lymphocyte regulation
- The role of hypoxia in cell death and inflammation
- The role of ribosylation in co-ordinating cell death and inflammation
- Understanding Plasmodium falciparum invasion of red blood cells
- Understanding cellular-cross talk within a tumour microenvironment
- Understanding the genetics of neutrophil maturation
- Understanding the roles of E3 ubiquitin ligases in health and disease
- Unveiling the heterogeneity of small cell lung cancer
- Using combination immunotherapy to tackle heterogeneous brain tumours
- Using intravital microscopy for immunotherapy against brain tumours
- Using nanobodies to understand malaria invasion and transmission
- Using structural biology to understand programmed cell death
- Validation and application of serological markers of previous exposure to malaria
- School resources
- Frequently asked questions
- Student profiles
- Abebe Fola
- Andrew Baldi
- Anna Gabrielyan
- Ashley Weir
- Bridget Dorizzi
- Casey Ah-Cann
- Catia Pierotti
- Emma Nolan
- Huon Wong
- Jasmine Rou
- Jing Deng
- Joy Liu
- Kaiseal Sarson-Lawrence
- Komal Patel
- Krishneel Prasa
- Lilly Backshell
- Malvika Kharbanda
- Megan Kent
- Naomi Jones
- Pailene Lim
- Rebecca Delconte
- Roberto Bonelli
- Rune Larsen
- Runyu Mao
- Sarah Garner
- Simona Seizova
- Sophie Collard
- Wayne Cawthorne
- Wil Lehmann
- Yanxiang Meng
- Zhong Yan Gan
- Miles Horton
- Alexandra Gurzau
- Student achievements
- Student association
- Learning Hub
- News
- Donate
- Online donation
- Ways to support
- Support outcomes
- Supporter stories
- Rotarians against breast cancer
- A partnership to improve treatments for cancer patients
- 20 years of cancer research support from the Helpman family
- A generous gift from a cancer survivor
- A generous vision for impactful medical research
- A gift to support excellence in Australian medical research
- An enduring friendship
- Anonymous donor helps bridge the 'valley of death'
- Philanthropy through the power of sisterhood
- Renewed support for HIV eradication project
- Searching for solutions to muscular dystrophy
- Supporting research into better treatments for colon cancer
- Taking a single cell focus with the DROP-seq
- Donors
- WEHI.TV
Antibodies, alpacas and COVID-19 - FAQs
WEHI researchers are studying 'nanobodies' - unique antibodies produced by alpacas - in a bid to understand whether they might be effective in blocking SARS-CoV-2, the virus that causes COVID-19.
FAQs
-
What is the difference between an antibody based therapy and an anti-viral treatment?
-
What is the difference between an antibody-based therapy and a vaccine?
-
How do nanobodies help in the development of treatments for COVID-19?
-
Can alpaca nanobodies be used to treat COVID-19 infection in humans?
-
How long will it take for this treatment to be used in humans?
-
Do the alpacas pose a COVID-19 risk to humans, livestock or native animals?
What are antibody-based therapies?
Antibody-based therapies, sometimes called ‘biologics’, are medicines that mimic antibodies – naturally occurring immune proteins – to fight infection. Antibody-based therapies are already in clinical use for diseases such as cancer and inflammatory and autoimmune conditions, including rheumatoid arthritis.
Why do we need antibody-based therapies for COVID-19?
Antibody-based therapies can be used both to prevent and treat COVID-19. They are particularly useful in older people or those who are immunocompromised and may not be able to mount a robust immune response to a vaccine.
While antibody-based therapies could be very effective in treating or preventing COVID-19 infection, they are only effective while the therapy is being administered and for a short time after therapy ceases and would not provide long-term protection, as something like a vaccine could.
What is the difference between an antibody-based therapy and an anti-viral treatment?
Antibody-based therapies can be used for treating a number of diseases, not just viral infections. Antibody-based therapies that are used to prevent or treat virus infections are one type of anti-viral treatment.
What is the difference between an antibody-based therapy and a vaccine?
Vaccines elicit an immune response in humans to produce antibodies, whereas antibody-based therapies deliver the effective antibodies directly.
Vaccines are often able to provide long-term protection, while antibody-based therapies only offer protection while the therapy is administered, and for a short time after it ceases.
Both vaccines and antibody-based therapies (and other potential treatments) would prove useful in the ongoing response to the COVID-19 pandemic.
What are nanobodies?
Members of the camelid family (alpacas, llamas, camels) make unique antibodies – nanobodies – that are smaller than conventional antibodies.
Conventional antibodies are composed of two immunoglobin – heavy chains and light chains – whereas alpacas make the majority of antibodies that lack the light chains. Nanobodies are laboratory-made antibody fragments of the heavy chain only domain that recognizes foreign proteins. Nanobodies are excellent for the investigation of novel anti-viral therapies because they are highly specific and stable.
How do nanobodies help in the development of treatments for COVID-19?
In this research, alpacas are immunised with a non-infectious ‘replica’ of the spike protein that is found on the surface of the SARS-CoV-2 virus (the virus that causes COVID-19) to produce antibodies. Our researchers extract the gene sequences encoding the nanobodies and use this to produce millions of types of nanobodies in the laboratory to select for the ones that bind to spike protein. They test the effectiveness of each nanobody to find those that are most effective in preventing or inhibiting the virus from entering cells. The ‘best’ nanobodies undergo further testing to evaluate their suitability for development into an antibody-based therapy that could safely and effectively be used in humans.
Can alpaca nanobodies be used to treat COVID-19 infection in humans?
No. However, once we know which nanobodies are the most potent in blocking the virus, we can use this information to develop next-generation nanobodies that mimic human antibodies to develop antibody-based therapies that could safely and effectively be used in humans in the future.
How long will it take for this treatment to be used in humans?
We are in the early stages of this research. There are a number of steps that need to take place, including clinical trials, before this antibody-based therapy could be used in humans. However, we are hopeful antibody-based therapies could offer one potential solution to COVID-19 and could be used alongside other treatment methods to combat this global pandemic.
Are the alpacas infected with COVID-19?
No.
The research team are not immunising the alpacas with SARS-CoV-2, which is the infectious virus that causes COVID-19. The alpacas are immunised with a synthetic and non-infectious version of the ‘spike’ protein that is found on the surface of the coronavirus. This synthetic ‘spike’ protein does not come from the virus itself, so is not capable of causing COVID-19 infection or disease in the alpacas.
Do the alpacas pose a COVID-19 risk to humans, livestock or native animals?
The alpacas pose absolutely no COVID-19 risk to humans or other livestock. They are not infected with the virus that causes COVID-19, or any part of the virus that causes COVID-19, and therefore it is not possible for them to infect humans, livestock or other animals with the disease.
As with all our research, health and safety is paramount and we abide by all relevant safety regulations at both a state and federal level. All Institute research involving animals complies with strict guidelines and legislation to protect the welfare of animals and ensure that animals are cared for in an ethical and humane way.
Who else is involved in this research consortium?
The research program brings together the expertise of Victorian and Australian academic and industry leaders in infectious diseases and antibody therapeutics, at the Walter and Eliza Hall Institute, the Doherty Institute, CSL, Affinity Bio, CSIRO, the Burnet Institute and the Kirby Institute.
The research has been funded by the Medical Research Future Fund and the Victorian Government.